Stockscreener 앱 받기
8.37
4.67%
-0.41
시간 외 거래:
8.37
전일 마감가:
$8.78
열려 있는:
$8.75
하루 거래량:
9.96M
Relative Volume:
1.19
시가총액:
$1.36B
수익:
$847.25M
순이익/손실:
$-284.86M
주가수익비율:
-3.655
EPS:
-2.29
순현금흐름:
$-112.35M
1주 성능:
+27.59%
1개월 성능:
+18.89%
6개월 성능:
+2.95%
1년 성능:
-28.34%
1일 변동 폭
$8.28
$9.1278
1주일 범위
$6.545
$9.1278
52주 변동 폭
$5.01
$15.22
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
NVAX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.37 | 1.23B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
Novavax slips as Citi launches with Sell rating on pipeline concerns - MSN
Novavax’s Q2 Financial Success: A Game Changer? - StocksToTrade
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View - Yahoo Finance
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Novavax Reports Strong Earnings Amid Strategic Shifts - TipRanks
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax: Q2 Earnings Snapshot - Connecticut Post
Novavax Q2 2025 Earnings Call Transcript - MarketBeat
Novavax (NVAX) Profit Jumps on Milestone - The Globe and Mail
Novavax raises 2025 revenue target to $1.05B with milestone payments and streamlined expenses as Sanofi partnership progresses - MSN
Novavax (NVAX) Reports Q2 Progress and Key Partnership Developme - GuruFocus
Transcript : Novavax, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Novavax expects post-marketing Covid study to cost up to $90M - Endpoints News
Novavax stock surges as HHS pulls mRNA vaccine funding, opening doors for alternative technologies - The Business Journals
Novavax outlook 2025 adjusted revenue $1 bln to $1.05 bln versus IBES estimate $1.02 bln - MarketScreener
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification - Investing.com India
Novavax banks on vaccine supply partnerships to boost 2025 revenue - Reuters
Novavax Shares Rise Following Avian Flu Vaccine Success - StocksToTrade
Novavax’s Vaccine Breakthrough Signals Optimism Amid Changing Market Dynamics - timothysykes.com
Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales - Yahoo Finance
Novavax (NVAX) Boosts 2025 Revenue Outlook Amid Strategic Collab - GuruFocus
Earnings call transcript: Novavax Q2 2025 reports unexpected profit, stock surges - Investing.com Canada
Novavax Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Can Novavax’s Innovation Fuel a Stock Rebound? - StocksToTrade
Novavax Q2 2025 slides: Milestone revenue drives profit amid strategic shift - Investing.com Australia
Novavax Q2 Earnings, Revenue Fall; Full-Year Adjusted Revenue Outlook Raised - MarketScreener
Novavax (NVAX) Raises Revenue Forecast Amid Strong Vaccine Partn - GuruFocus
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Novavax (NVAX) Surpasses Earnings Expectations with Revenue Boos - GuruFocus
Earnings snapshot: Novavax tops Q2 estimates; raises full-year outlook - MSN
Novavax stock higher on Q2 beat, guidance (NVAX:NASDAQ) - Seeking Alpha
Novavax raises annual revenue forecast on vaccine supply partnerships - Reuters
Novavax lifts 2025 revenue outlook after FDA milestone payment By Investing.com - Investing.com Canada
Novavax earnings beat by $0.68, revenue topped estimates - Investing.com Canada
Novavax Inc (NVAX) Q2 2025 Earnings: EPS of $0.62 Beats Estimate, Revenue Surges to $239 Million - GuruFocus
Novavax Reports Second Quarter 2025 Financial Results and Operat - GuruFocus
Novavax's Strategic Transformation and Revenue Catalysts in 2025: A High-Conviction Play in Vaccine Innovation - AInvest
Novavax beats quarterly revenue estimates on milestone payment - Yahoo Finance
Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener
Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights - TradingView
Earnings Flash (NVAX) Novavax Posts Q2 Revenue $239.2M, vs. FactSet Est of $152.6M - MarketScreener
NOVAVAX INC SEC 10-Q Report - TradingView
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Novavax Q2 2025 Earnings Preview - MSN
Novavax (NVAX) Prepares for Q2 Earnings Report Amid Earnings His - GuruFocus
What are analysts’ price targets for Novavax Inc. in the next 12 monthsCapitalize on strong market momentum - Jammu Links News
What are Novavax Inc. company’s key revenue driversUnlock exclusive stock market forecasts - Jammu Links News
What analysts say about Novavax Inc. stockCapitalize on market momentum for profits - Jammu Links News
Why is Novavax Inc. stock attracting strong analyst attentionGrow your wealth with proven stock picks - Jammu Links News
Is Novavax Inc. stock overvalued or undervaluedSuperior investment outcomes - Jammu Links News
Novavax, Inc.'s (NASDAQ:NVAX) latest 12% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):